Dyadic International Inc
NASDAQ:DYAI
Dyadic International Inc
Revenue
Dyadic International Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Dyadic International Inc
NASDAQ:DYAI
|
Revenue
$2.9m
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-16%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Dyadic International Inc
Revenue Breakdown
Breakdown by Geography
Dyadic International Inc
Breakdown by Segments
Dyadic International Inc
Total Revenue:
2.9m
USD
|
Research And Development:
2.5m
USD
|
License:
352.9k
USD
|
See Also
What is Dyadic International Inc's Revenue?
Revenue
2.9m
USD
Based on the financial report for Dec 31, 2023, Dyadic International Inc's Revenue amounts to 2.9m USD.
What is Dyadic International Inc's Revenue growth rate?
Revenue CAGR 10Y
-16%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Dyadic International Inc have been 22% over the past three years , 17% over the past five years , and -16% over the past ten years .